Zacks Upgrades Applied Materials and Biotech Stocks to Buy Ratings

Zacks Investment Research has upgraded Applied Materials (AMAT) to a "Strong Buy" (Zacks Rank #1), signaling robust growth potential for the semiconductor equipment giant. The upgrade cycle also extended to the biotechnology sector, with Galectin Therapeutics (GALT) and Vivani Medical (VANI) both raised to a "Buy" rating (Zacks Rank #2). These revisions are primarily driven by improving future earnings prospects and upward adjustments in analyst estimates. Zacks' ranking system focuses on earnings estimate revisions, which are often considered a reliable precursor to stock price appreciation. The positive outlook for Applied Materials reflects underlying strength in the tech sector, while the biotech upgrades highlight specific fundamental progress in clinical-stage firms. Investors typically view these quantitative rank changes as a signal of positive momentum in the underlying business performance.